Stay updated with breaking news from John Markels. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dr. Markels, accomplished and experienced industry executive, most recently President of Global Vaccines at Merck, to provide strategic oversight to the Company’s vaccine franchiseSAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical m...
Nordea Investment Management AB increased its position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Rating) by 5.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 648,430 shares of the biopharmaceutical company’s stock after acquiring an additional 32,988 shares during the quarter. Nordea Investment Management […]
Sangamo Therapeutics (NASDAQ:SGMO – Get Rating) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Saturday. A number of other research firms have also recently commented on SGMO. Truist Financial dropped their target price on Sangamo Therapeutics from $23.00 to $19.00 and set a “buy” rating […]
Equities analysts forecast that Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Rating) will announce $23.27 million in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest sales estimate coming in at $17.00 million and the highest estimate coming in at $28.50 million. Sangamo Therapeutics posted sales […]
Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Rating) Director John Markels bought 6,784 shares of Sangamo Therapeutics stock in a transaction dated Friday, June 3rd. The stock was acquired at an average price of $3.69 per share, with a total value of $25,032.96. Following the purchase, the director now directly owns 32,484 shares of the company’s […]